Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bushu Pharm. to Start Independent PR Activities
August 22, 2005
- Approval of 5 Anticancer Agents Discussed
August 22, 2005
- BUSINESS NEWS IN BRIEF
August 22, 2005
- Nippon Chemiphar Announces New 3-Year Management Plan
August 22, 2005
- More than 400 Medical Institutions Issue GE Name Prescriptions
August 22, 2005
- MediciNova Starts PII Trial of Ibudilast for MS
August 22, 2005
- Burgeoning Clinical Trial Business in China
August 22, 2005
- List of Issues to Be Discussed Proposed by Korosho
August 8, 2005
- SEMINAR
August 8, 2005
- Proposed Issues to Be Discussed for Reform of the NHI Pricing System
August 8, 2005
- Tablets Associated with Better Compliance: Cancer Pain Survey
August 8, 2005
- Import of Banyu's Propecia Recommended for Approval
August 8, 2005
- REGULATORY NEWS IN BRIEF
August 8, 2005
- 1st Qtr Business Results
August 8, 2005
- Average Salary Hikes in 2005 Slightly Down from 2004: Survey
August 8, 2005
- Fujifilm Subsidiary to Launch Package Insert Design Software
August 8, 2005
- Doctors' Influence on Drug Selection Is Decreasing: Mr Baba
August 8, 2005
- BUSINESS NEWS IN BRIEF
August 8, 2005
- NEW PRODUCTS
August 8, 2005
- 4th Scientific Meeting of Japan Society of Generic Medicine
August 8, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…